The latest clinical trials into novel AML therapies

The latest clinical trials into novel AML therapies

VJHemOnc

2 years
283 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the new and exciting clinical trials that are currently underway for the treatment of acute myeloid leukemia (AML), including a Phase I study of isocitrate dehydrogenase (IDH) inhibitors in combination with induction chemotherapy, a Phase III study investigating low dose cytarabine and venetoclax, and the ADMIRAL study (NCT02421939) of the FLT3 inhibitor, gilteritnib, versus salvage chemotherapy in relapsed and refractory AML. Dr Stein also conveys his excitement about the QuANTUM-R trial (NCT02039726), which is investigating the effects of quizartinib monotherapy versus salvage chemotherapy on overall survival rates. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay